Vinblastine is a medicine used to treat certain types of cancer. It works by stopping the growth of cancer cells. It is often used in combination with other treatments.
Every report comes from a Lived member, sent anonymously.
Have you tried Vinblastine for Hodgkin Lymphoma?
Vinblastine is a chemotherapy medicine, given into a vein, that is used to treat several cancers. Its best-known role is in Hodgkin lymphoma, a cancer of the lymph nodes. There it is one of the four drugs in ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine), a long-standing standard regimen, and it stays in newer regimens for advanced disease that replace bleomycin with nivolumab, an immunotherapy, or with brentuximab vedotin, an antibody that carries a cell-killing drug directly to lymphoma cells. It is also approved for other lymphomas, including advanced mycosis fungoides (a lymphoma that starts in the skin), advanced testicular cancer, Kaposi sarcoma, and Langerhans cell histiocytosis, a rare disorder in which certain immune cells build up and damage bone, skin or other organs. In children with Langerhans cell histiocytosis that needs drug treatment, vinblastine combined with the steroid prednisone is the most commonly used chemotherapy. Less often it is used for choriocarcinoma (a cancer that grows from pregnancy tissue) or breast cancer that has not responded to other treatments, and doctors sometimes use it off label for bladder, lung or certain brain tumors. Vinblastine is almost always given together with other cancer medicines, because drugs that attack cancer cells in different ways work better in combination than one drug alone. It was once sold under the brand name Velban, which is no longer marketed in the US; it is now available as generic vinblastine sulfate.
Vinblastine belongs to a group of chemotherapy drugs called vinca alkaloids. When a cell divides, it builds microtubules, tiny protein rods that form a scaffold to pull its copied chromosomes into the two new cells. Vinblastine stops these rods from forming, so a dividing cell stalls partway through division and cannot complete it. Cancer cells that divide often are especially vulnerable, but healthy cells that divide quickly are affected too. The most important of these are the bone marrow cells that make white blood cells, which is why a temporary drop in infection-fighting cells is the main side effect. Laboratory studies suggest vinblastine also has other effects inside cells, and its benefit against tumors is not fully explained by blocking cell division alone.
Vinblastine is given only into a vein (intravenously), by an oncology nurse or doctor in a clinic or hospital, usually as a short infusion lasting minutes rather than hours. It must never be injected into the spinal fluid: given that way it is usually fatal, which is why it is prepared and labeled with special safeguards against that mistake. The dose is calculated from body size and depends on the cancer and the regimen. Doses are given no more often than once a week, and schedules range from weekly to every few weeks. A blood count is checked before each dose; if white blood cells have not recovered enough, the dose is delayed or lowered. Doses are also reduced for people with significant liver problems, because the liver clears the drug.
The most common and important effect is a fall in white blood cells, which fight infection. Counts usually reach their lowest point 5 to 10 days after a dose and recover over the following one to two weeks. A fever, chills, sore throat or mouth sores during treatment can signal an infection and should be reported to the care team right away, including outside office hours. Other common effects include constipation, nausea, loss of appetite, tiredness, partial hair loss (hair often regrows even while treatment continues) and aching in the jaw, bones or areas where the tumor is. Vinblastine can slow the bowel, so preventing constipation is part of the plan; severe abdominal pain or constipation that does not respond to the usual measures should be reported promptly. Nerve effects are less common but can last longer and be disabling: numbness or tingling in the fingers and toes, loss of reflexes, unsteady walking and, rarely, hearing loss or balance problems that may be permanent. Mention these to the care team as soon as they appear, since the dose or plan may need to change. If the drug leaks out of the vein during the infusion, it can seriously irritate the skin and underlying tissue. Tell the nurse at once about pain, burning, redness or swelling at the IV site, and call the care team if any of these appear after you leave. Sudden trouble breathing, chest pain or a seizure needs emergency care: call 911.
The liver breaks vinblastine down using a specific family of enzymes. Medicines that block those enzymes, such as the antibiotic erythromycin, can raise vinblastine levels and make side effects arrive sooner or more severely, and liver disease has a similar effect. Chemotherapy combinations containing vinblastine can also lower blood levels of phenytoin, an anti-seizure medicine, so those levels need checking. Give the care team a full list of prescription, over-the-counter and herbal products before starting. Some combinations carry particular risks. With mitomycin, another chemotherapy drug, vinca alkaloids have caused sudden severe breathing problems. The vinblastine, bleomycin and cisplatin combination used for testicular cancer has been linked to rare heart attacks and strokes, and to Raynaud phenomenon (fingers turning white or blue in the cold); adding cisplatin, a platinum drug, also raises the risk of hearing damage. Vinblastine is not started during an uncontrolled bacterial infection, or when white blood cells are already very low unless the cancer itself is the cause. It can harm a developing baby, so pregnancy should be avoided during treatment, and breastfeeding is not recommended. It can also disrupt menstrual periods and stop sperm production, sometimes permanently, so fertility is worth discussing before treatment begins.
Vinblastine is given in repeated cycles as part of a plan set by the oncology team. Each visit usually includes a blood count, a check on how you have been feeling and the infusion itself. Side effects tend to follow the rhythm of the cycle: aches and tiredness in the first days, the lowest blood counts about a week or so after a dose, then recovery before the next one. How long treatment lasts depends on the condition and regimen. Hodgkin lymphoma regimens run for a set number of cycles, while children with Langerhans cell histiocytosis who respond well commonly receive about 12 months of vinblastine and prednisone. Nerve symptoms can outlast other side effects, so report new numbness, balance trouble or hearing changes at each visit rather than waiting. The goal of treatment, whether cure or control, depends on the cancer and its stage. Results in advanced Hodgkin lymphoma are generally good: in a large recent trial of people with previously untreated advanced disease, 92 percent of those given nivolumab with vinblastine-containing chemotherapy, and 83 percent of those given brentuximab vedotin with the same chemotherapy, were alive without their lymphoma progressing two years later.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Vinblastine, what you've noticed, or ask the community a question.